Department Metrics

• Characterizing Cytotoxic Therapy Induced Shifts in the Cost-to-Benefit Ratio of High Ploidy
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Andor, N.
• Modeling the Role and Regulation of Reactive Stroma in Breast Ductal Carcinoma Microinvasions
  Award Number:
  Sponsor: Nat Institutes of Health
  PI:Rejniak, K.
• The Delta Ecology of NSCLC Treatment
  Award Number:
  Sponsor: Nat Institutes of Health
  PI (Contact):Anderson, A.,PI (MPI):Gatenby, R.,Project PI:Marusyk, A.

CLINICAL TRIAL 20117
A Phase 1/2 Study of Regn5678 (Anti-psmaxcd28) with Cemiplimab (Anti-pd-1) in Patients with Metastatic Castration-Resistant Prostate Cancer
Condition: Genitourinary
Intervention: Cemiplimab (); REGN2810 (Cemiplimab); REGN5678 (); Sarilumab (); [18]F-DCFPyL ()

CLINICAL TRIAL 22254
A Phase 2 Multi-Cohort, Open-Label, Multi-Center Clinical Study Evaluating the Efficacy and Safety of Disitamab Vedotin (RC48-ADC) Alone or in Combination with Pembrolizumab in Subjects with Locally-Advanced Unresectable or Metastatic Urothelial Carcinoma That Expresses HER2
Condition: Genitourinary
Intervention: Disitamab Vedotin (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 22344
A Phase I Clinical Trial of an Infusion of Autologous gamma delta T cells Genetically Engineered with a Chimeric Receptor to Target the Prostate Stem Cell Antigen in Patients with Metastatic Castration Resistant Prostate Cancer
Condition: Genitourinary
Intervention: MSGV1-PSCA-8T28Z (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 22350
A Phase I/II Open Label Study to Evaluate the Safety, Cellular Kinetics, and Efficacy of AZD0754, a Chimeric Antigen Receptor (CAR) T-cell Therapy Directed Against STEAP2, in Adult Participants with Metastatic Prostate Cancer: APOLLO
Condition: Genitourinary
Intervention: AZD0754 (); AZD2287 (); cyclophosphamide (); cytoxan (cyclophosphamide); fludarabine (Fludarabine phosphate)

CLINICAL TRIAL 23055
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of FB849 Administered in Subjects with Advanced Solid Tumors Alone and in Combination with Pembrolizumab
Condition: Genitourinary
Intervention: FB849 (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 23757
A Randomised, Double-blind, Placebo-controlled, Phase III Study of Adjuvant Saruparib (AZD5305) in Patients with BRCAm Localised High-Risk Prostate Cancer Receiving Radiotherapy with Androgen Deprivation Therapy (EvoPAR-Prostate02)
Condition: Genitourinary
Intervention: ADT (); Abiraterone (); Placebo (); Saruparib ()

CLINICAL TRIAL 23644
A Phase 3 Randomized, Double-blind, Placebo-controlled Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, + Best Supportive Care Versus Best Supportive Care for Metastatic Castration-resistant Prostate Cancer
Condition: Genitourinary
Intervention: JNJ-87189401 (); Pasritamig (); Placebo ()

CLINICAL TRIAL 23692
A Phase 1 Study to Assess the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of ACE-232 in Patients with Metastatic Castration-Resistant Prostate Cancer (CRPC)
Condition: Genitourinary
Intervention: ACE-232 ()

CLINICAL TRIAL 23715
A Phase I/II Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-engaging Antibody That Targets STEAP2, CD3, and CD8 in Adult Participants With Metastatic Prostate Cancer (ACTIVATED-4-PC)
Condition: Genitourinary
Intervention: AZD6621 ()

CLINICAL TRIAL 23731
A Phase 2a Multicenter Dose Escalation and Dose Optimization Study of SYNC-T Therapy SV-102 for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (LEGION-100-2a)
Condition: Genitourinary
Intervention: SV-102 ()

CLINICAL TRIAL 23775
A Phase 2a Study of High Dose Testosterone followed by Targeted Radioligand Therapy in Metastatic Castration Resistant Prostate Cancer
Condition: Genitourinary
Intervention: Decapeptyl SR (Triptorelin); Degarelix (); Eligard (Leuprolide); Leuprolide (); Luteinizing hormone-releasing hormone (LHRH) analog (); PSMA-617 (); Relugolix (Orgovyx); Testosterone cypionate (); Triptorelin ()

CLINICAL TRIAL 23930
A Phase 3, Open-label, Multicenter, Randomized Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
Condition: Genitourinary
Intervention: Abiraterone acetate (); Cabazitaxel (); Jevtana (Cabazitaxel); Taxotere (docetaxel); Xaluritamig (); Zytiga (Abiraterone acetate); docetaxel ()

CLINICAL TRIAL 24017
A phase 1/2, first-in-human study to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of AVZO-103, a Nectin4/Trop2 ADC, as a single agent and in combination therapy in patients with locally advanced or metastatic urothelial cancer or other solid tumors
Condition: Genitourinary
Intervention: AVZO-103 (); Pembrolizumab (Keytruda)

CLINICAL TRIAL 24204
Phase 1/2 Study of REGN15505 (a PSMAx4-1BB Bispecific Antibody) Administered Alone or in Combination with Cemiplimab or REGN4336 (a PSMAxCD3 Bispecific Antibody) in Patients with Metastatic Castration-Resistant Prostate Cancer and Clear Cell Renal Cell Carcinoma
Condition: Genitourinary
Intervention: Cemiplimab (); REGN15505 (); REGN2810 (Cemiplimab); REGN4336 ()

• Hatoum F, Dyer B, Heiligh J, Poehlman T, Zhang J, Jameel G, Mizelle S, Patel A, Schneider A, Fazili A, Johnson JS, Miller JW, Roman Souza G, Mahmoud N, Gullapalli K, Kim Y, Spiess PE, Gatenby R, Anderson ARA, Chahoud J. A phase II study assessing the feasibility and clinical efficacy of adaptive immunotherapy combination with VEGFR-TKI in patients with advanced renal cell carcinoma. Future Oncol. 2026 Sep.1-9. Pubmedid: 42719952.
• West J, Desai B, Strobl MAR, Gallaher J, Robertson-Tessi M, Marusyk A, Anderson ARA. Evolutionary Antifragile Therapy Is a Treatment Strategy to Suppress Drug Resistance by Exploiting Dose-Response Convexity. Cancer Res. 2026 Sep.86(17):4434-4445. Pubmedid: 42171656. Pmcid: PMC13283037.
• Hosny N, Li S, Gatenby RA, Pienta KJ, Brown JS, Hammarlund EU, Yu C, Qu J, Austin RH, Amend SR. Hypoxia-Responsive HIF-1α-Dependent RhoA Signaling Promotes Motility and Aerotaxis in Polyaneuploid PC3 Cancer Cells with Increased Nuclear Rounding. Biophys J. 2026 Sep. Pubmedid: 42693642.
• Downey ER, Forero Pinto AM, Booth AL, Brown J, Rejniak KA, Damaghi M. Symbiotic cancer cell-stroma crosstalk in the acidic tumor microenvironment. J Evol Biol. 2026 Aug. Pubmedid: 42631637.
• Gallagher K, Strobl MA, Gatenby RA, Zhang J, Maini PK, Anderson AR. Mathematical Biomarkers of Adaptive Therapy Outcomes in Prostate Cancer. JAMA Oncol. 2026 Aug. Pubmedid: 42560686. Pmcid: PMC13448836.
• Olumoyin KD, Park M, Davis EW, Permuth JB, Rejniak KA. MoCaPS: a machine learning model for stratification of cancer-associated cachexia based on blood biomarkers. NPJ Syst Biol Appl. 2026 Jul. Pubmedid: 42463688.
• Emond R, West J, Grolmusz VK, Cosgrove PA, Nath A, Anderson ARA, Bild AH. A novel combination therapy for ER+ breast cancer suppresses drug resistance via an evolutionary double-bind. Mol Syst Biol. 2026 Jul.22(7):1070-1096. Pubmedid: 41888569. Pmcid: PMC13328575.
• Arabzadeh M, Tang YH, Colin-Leitzinger C, Marzban S, Walgenbach D, Morganti S, Mahaganapathy V, Harper E, Teng M, Kresovich JK, Washington I, Parsons HA, Garber JE, West J, Ganesan S, Khiabanian H, Gillis N. Evolution of clonal hematopoiesis during cancer treatment and its impact on outcomes. J Clin Invest. 2026 Jul.136(14). Pubmedid: 42262879. Pmcid: PMC13367969.
• Garjani H, Dubbeldam J, Staňková K, Brown JS. Which evolutionary game-theoretic model best captures NSCLC dynamics?. PLoS One. 2026 Jun.21(6):e0347657. Pubmedid: 42224394. Pmcid: PMC13225666.
• Tagal V, Li T, Kumar R, Shrestha P, Yu X, Miroshnychenko D, Olumoyin K, Marusyk A, Davies M, Maudsley S, El-Naqa I, Gomes AP, Duckett DR, Han HS, Andor N. Ploidy shapes gemcitabine response through altered potency and delayed cell death. bioRxiv. 2026 Jun. Pubmedid: 42282758. Pmcid: PMC13251900.
• Kimmel GJ, Marzban S, Damaghi M, Traulsen A, Anderson ARA, West J, Altrock PM. Universal principles of cell population growth follow from local contact inhibition. iScience. 2026 Jun.29(6):115953. Pubmedid: 42205703. Pmcid: PMC13207371.
• Bhattacharya R, Bukkuri A, Gatenby RA, Brown JS. Cancer Evolvability Determines Therapy Outcomes. bioRxiv. 2026 May. Pubmedid: 42146465. Pmcid: PMC13174658.
• Desai B, Miti T, Prabhakaran S, Miroshnychenko D, Kumar P, Henry M, Marusyk V, Siqueira NSN, Gatenbee C, Ozakinci H, Bui M, Boyle TA, Scott J, Altrock PM, Pellini B, Haura E, Anderson ARA, Basanta D, Marusyk A. Multifactorial sheltering in peristromal niches shapes in vivo responses of lung cancers to targeted therapies. Nat Commun. 2026 May.17(1). Pubmedid: 42215447. Pmcid: PMC13392419.
• Kumar P, Henry M, Pelesko J, Desai B, Weh MT, Kakumanu R, Liu M, Nunes Siqueira NS, Velde RV, Marusyk V, Aurelio J, Haura E, Gray J, Pellini B, Basanta D, Marusyk A. Pharmacokinetic Acceleration via CYP3A4 Hyperactivation as a Clinically Actionable Mechanism of Targeted Therapy Resistance in NSCLC. bioRxiv. 2026 May. Pubmedid: 42239162. Pmcid: PMC13228325.
• Kimmel GJ, Marzban S, Damaghi M, Traulsen A, Anderson ARA, West J, Altrock PM. Universal principles of cell population growth follow from local contact inhibition. ArXiv. 2026 Apr. Pubmedid: 42038417. Pmcid: PMC13105202.
• Marzban S, Robertson-Tessi M, West J. Mechanistic learning to predict and understand minimal residual disease. bioRxiv. 2026 Apr. Pubmedid: 42079209. Pmcid: PMC13131804.
• Luddy KA, West J, Robertson-Tessi M, Desai B, Ojeda A, Newman H, Estrella V, Bursell TM, Barrett S, O'Sullivan J, Marignol L, Gatenby RA, Brown JS, Anderson AR, O'Farrelly C. Evolutionary Double-Bind Treatment Using Radiation Therapy and Natural Killer Cell-Based Immunotherapy in Prostate Cancer. Int J Radiat Oncol Biol Phys. 2026 Mar.124(3):702-716. Pubmedid: 40998270. Pmcid: PMC12908384.
• Prabhakaran S, Gatenbee CD, Robertson-Tessi M, Gahramanli Ozturk Z, Boyle TA, Gray JE, Antonia SJ, Gatenby RA, Beg AA, Anderson ARA. Distinct Tumor-Immune Ecologies in Patients with Lung Cancer Predict Progression and Define a Clinical Biomarker of Therapy Response. Cancer Res. 2026 Mar.86(5):1269-1285. Pubmedid: 41418101. Pmcid: PMC12871056.
• Marzban S, Stiehl T, Xie Z, Andersen M, Snyder J, Gudmand-Høyer J, Ottesen JT, Mon Père NV, Werner B, Huang W, DeZern AE, Sekeres MA, Walter MJ, Padron E, Gillis N, West J. Modeling the evolutionary dynamics of clonal hematopoiesis. Nat Genetics. 2026 Mar.58(3):481-491. Pubmedid: 41699138. Pmcid: PMC13069927.
• Veith T, Beck RJ, Brown JS, Andor N. Inverse game theory characterizes frequency-dependent selection driven by karyotypic diversity in triple-negative breast cancer. PLoS Comput Biol. 2026 Mar.22(3):e1013897. Pubmedid: 41805696. Pmcid: PMC13108871.
• Froid M, Branciamore S, Chen Z, Frankhouser D, Fu YH, Ambriz JR, Nguyen LXT, Irizarry J, Kuo YH, O'Meally D, Zhang B, Marcucci G, Rockne R, Basanta D. Overcoming vascular niche-mediated TKI resistance in acute myeloid leukemia through miR-126 inhibition. NPJ Syst Biol Appl. 2026 Mar.12(1). Pubmedid: 41857060. Pmcid: PMC13004950.
• Oluwatola O, Bazargan S, Irrera P, Chang D, Thomas A, Blauvelt J, Beatty M, Hall M, Whelan CJ, Estrella V, Rejniak KA, Poch M, Fitzsimmons N, Beal R, Ibrahim-Hashim A, Pilon-Thomas S. Transdermal bicarbonate buffer therapy increases intratumoral pH and elicits antitumor responses in bladder cancer. Front Immunol. 2026 Mar.17:1706250. Pubmedid: 41909665. Pmcid: PMC13021593.
• Olumoyin KD, Aydin AM, Bazargan S, Bunch B, Chamseddine I, Karolak A, Beatty M, Pilon-Thomas S, Poch MA, Rejniak KA. PETIL: Predicting Expansion of Tumor Infiltrating Lymphocytes for the Adoptive Cell Immunotherapy in Bladder Cancers. bioRxiv. 2026 Mar. Pubmedid: 41959383. Pmcid: PMC13060882.
• Anderson HG, Bazargan S, Nusbaum DJ, Poch MA, Pilon-Thomas S, Rejniak KA. A virtual cohort framework with applications to adoptive cell therapy in bladder cancer. bioRxiv. 2026 Mar. Pubmedid: 41959223. Pmcid: PMC13060980.
• Luddy K, Newman H, Gravon J, Robertson-Tessi M, Gatenby R. Radiopharmaceutical Therapy and Immunotherapy Combinations Utilizing Cancer Evolution and Computational Modeling in Metastatic Prostate Cancer. PET Clin. 2026 Jan.21(1):169-180. Pubmedid: 41136296.
• Gravenmier C, Marzban S, Tang YH, Gillis N, Shah BD, Moscinski LC, Zhang L, West J. Cell State Transitions Drive the Evolution of Disease Progression in B-Lymphoblastic Leukemia. Cancer Res Commun. 2026 Jan.6(1):47-59. Pubmedid: 41295979. Pmcid: PMC12775648.
• Bekker RA, Brady-Nicholls R, de Pillis L, Gevertz JL, Jain HV. Integrating machine learning into the in silico clinical trial pipeline. Math Biosci. 2026 Jan.391:109583. Pubmedid: 41308950.
• Pradelli F, Strobl M, Marzban S, de Kermenguy F, Barnett A, Ganesan K, Lorenzo G, Hormuth DA, Hamis S, Bhaskar D, Anderson ARA, West J. 75 Years of Mathematical Oncology. bioRxiv. 2026 Jan. Pubmedid: 41648173. Pmcid: PMC12871332.
• Schneider K, Spekking L, Azimi S, Peltanová B, Rösel D, Brown JS, Gatenby RA, Brábek J, Staňková K. Migrastatic therapy as a potential game-changer in adaptive cancer treatment. Sci Rep. 2026 Jan.16(1):3929. Pubmedid: 41484230. Pmcid: PMC12855177.
• Gevertz JL, Jain HV, Kareva I, Wilkie KP, Brown J, Huang YP, Sontag E, Vinogradov V, Davies M. Delaying cancer progression by integrating toxicity constraints in a model of adaptive therapy. NPJ Syst Biol Appl. 2026 Jan.12(1):11. Pubmedid: 41501069. Pmcid: PMC12820236.
• Rockne RC, Andersen M, Anderson ARA, Basanta D, Bentivegna A, Benzekry S, Branciamore S, Brüningk SC, Conte M, Farahpour F, Karolak A, Köhn-Luque A, Lorenzo G, Manookian B, Rodin AS, Schmalenstroer L, Soler J, Tomasetti C, Urbaniak K. The future of mathematical oncology in the age of AI. NPJ Syst Biol Appl. 2026 Jan.12(1):22. Pubmedid: 41588010. Pmcid: PMC12890909.
• Scibilia KR, Gallagher K, Masud MA, Robertson-Tessi M, Gatenbee CD, West J, Llamas P, Prabhakaran S, Gallaher J, Anderson ARA. Mathematical Oncology: How Modeling Is Transforming Clinical Decision-Making. Cancer Res. 2025 Dec.85(24):4866-4879. Pubmedid: 41105675. Pmcid: PMC12614879.
• Gatenby RA, Anderson ARA, Brown JS, Gallaher J, Krolick J, Lemanne D. Directed Evolution Restored Castrate Sensitivity in a Patient With Castrate Resistant Metastatic Prostate Cancer. Prostate. 2025 Dec.85(16):1562-1567. Pubmedid: 40878050.
• Olumoyin KD, Park M, Davis EW, Permuth JB, Rejniak KA. Machine Learning-Based Identification of Blood Biomarkers that Distinguish Precachectic and Cachectic Patients with Pancreatic Ductal Adenocarcinoma. medRxiv. 2025 Dec. Pubmedid: 41480031. Pmcid: PMC12755264.
• Park MA, Davis EW, Alhassan S, Arnoletti JP, Basinski TL, McKee AB, Bloomston M, Carson TL, Biachi de Castria T, Chen DT, Cortizas EM, Crowder SL, Delgado MG, Douglas WG, Fleming JB, Hodul P, Huguet KL, Jiang K, Kim DW, Koomen J, Luthra AK, Malafa M, Menon AA, Morales R, Merchant NB, Meredith K, Mo Q, Molina-Vega MA, Moreno-Urazan L, Olumoyin KD, Parker N, Pimiento JM, Rasool G, Rejniak KA, Sansil S, Sparks LM, Stewart P, Tassielli AF, Teer JK, Tran DV, Trevino JG, Velanovich V, Whelan CJ, Jeong D, Judge SM, Judge AR, Permuth JB. Race-based differences in serum biomarkers for cancer-associated cachexia in a diverse cohort of patients with pancreatic ductal adenocarcinoma. Commun Med (Lond). 2025 Dec.6(1):19. Pubmedid: 41413302. Pmcid: PMC12789063.
• Olumoyin K, El Naqa L, Rejniak K. Learning Model Parameter Dynamics in a Combination Therapy for Bladder Cancer from Sparse Biological Data. ArXiv. 2025 Dec. Pubmedid: 41445818. Pmcid: PMC12723788.
• Beck RJ, Li T, Andor N. ALFA-K: Local adaptive mapping of karyotype fitness landscapes. Nat Commun. 2025 Dec.17(1):1015. Pubmedid: 41455703. Pmcid: PMC12848095.
• Pergams A, Haus M, Estrada C, Brown J, Salles A. Dinner Date: Opposite-Sex Pairs of Fruit Bats (Rousettus aegyptiacus) Forage More than Same-Sex Pairs. Biology (Basel). 2025 Dec.14(12). Pubmedid: 41463515. Pmcid: PMC12730429.
• Obertopp N, Froid M, Pilon-Thomas S, Basanta D. Rethinking the seven-day treatment-free interval in T-cell engager therapy using agent-based modeling. bioRxiv. 2025 Nov. Pubmedid: 41332775. Pmcid: PMC12667981.
• Hosny N, Shen K, Zhao Y, Qu J, Sun Y, Butler G, Amend S, Hammarlund EU, Gatenby R, Brown J, Pienta KJ, Phan TV, Boyer-Paulet S, Li S, Austin RH. Protocol to model tumor hypoxia in vitro using real-time phosphorescence-based sensing of O2 gradients generated by metastatic cancer cells. STAR Protoc. 2025 Oct.6(4):104163. Pubmedid: 41150854. Pmcid: PMC12597275.
• Olumoyin K, Rejniak K. Modeling Adoptive Cell Therapy in Bladder Cancer from Sparse Biological Data using PINNs. ArXiv. 2025 Oct. Pubmedid: 41281226. Pmcid: PMC12633144.
• Beck R, Tagal V, Amin S, Bakhoum SF, Maley C, Verhaak RGW, Gomes AP, Andor N. Energetics of whole genome doubling and genomic instability. Cancer Lett. 2025 Oct.630:217878. Pubmedid: 40517938.
• Gallagher K, Strobl MAR, Anderson ARA, Maini PK. Deriving Optimal Treatment Timing for Adaptive Therapy: Matching the Model to the Tumor Dynamics. Bull Math Biol. 2025 Sep.87(10):146. Pubmedid: 40921859. Pmcid: PMC12417256.
• Arabzadeh M, Tang YH, Colin-Leitzinger C, Marzban S, Walgenbach D, Morganti S, Mahaganapathy V, Harper E, Teng M, Kresovich JK, Washington I, Parsons HA, Garber JE, West J, Ganesan S, Khiabanian H, Gillis N. Clonal Hematopoiesis Dynamics and Evolutionary Fitness During Cancer Treatment Impact Clinical Outcomes. medRxiv. 2025 Sep. Pubmedid: 40950448. Pmcid: PMC12424905.
• West J, Desai B, Strobl M, Gallaher J, Robertson-Tessi M, Marusyk A, Anderson ARA. Evolutionary antifragile therapy. bioRxiv. 2025 Sep. Pubmedid: 41000654. Pmcid: PMC12458151.